Neurocrine Biosciences | NBIX - Interest Expense On Debt



Neurocrine Biosciences reported $1.1M in Interest Expense on Debt for its fiscal quarter ending in March of 2024.

Interest Expense On Debt Change Date
AbbVie USD 591M 135M Sep/2024
ALKERMES USD 6M 50K Sep/2024
Alnylam Pharmaceuticals USD 34.38M 1.12M Sep/2024
Amgen USD 90.88B 24M Sep/2024
Biogen USD 59.8M 1.5M Sep/2024
BioMarin Pharmaceutical USD 2.97M 602K Sep/2024
Cytokinetics USD 22.3M 9.57M Sep/2024
Dynavax Technologies USD 1.7M 1000 Sep/2024
Gilead Sciences USD 238M 1000K Sep/2024
Halozyme Therapeutics USD 4.52M 4K Sep/2024
Incyte USD 774K 117K Sep/2024
Ionis Pharmaceuticals USD 19M 1000K Sep/2024
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Pfizer USD 784M 6M Sep/2024
Regeneron Pharmaceuticals USD 13.8M 1000K Sep/2024
Repligen USD 5.55M 50K Sep/2024
Sarepta Therapeutics USD 4.92M 86K Sep/2024
Teva Pharmaceutical Industries USD 241M 9M Jun/2024
Ultragenyx Pharmaceutical 15.71M 14.11M Sep/2024
Vertex Pharmaceuticals USD 7.5M 2.4M Sep/2024